A Phase I, Double-blind, Randomized, Placebo-controlled, Study to Evaluate the Safety and Immunogenicity of AERAS-456 in HIV Negative Adults Successfully Treated for Drug-susceptible Pulmonary Tuberculosis
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs H56IC (Primary)
- Indications Pulmonary tuberculosis
- Focus Adverse reactions
- Sponsors Aeras
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 03 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Oct 2016.
- 13 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.